ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The brokerage presently has a $5.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 15.38% from the stock’s current price.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

Several other research firms have also recently weighed in on ZIOP. HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. ValuEngine cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $12.58.

Shares of ZIOPHARM Oncology (ZIOP) traded down $0.17 on Friday, reaching $4.55. The company’s stock had a trading volume of 1,483,552 shares, compared to its average volume of 1,639,527. ZIOPHARM Oncology has a 12-month low of $4.34 and a 12-month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the business posted ($0.11) EPS. ZIOPHARM Oncology’s quarterly revenue was up .0% on a year-over-year basis. sell-side analysts expect that ZIOPHARM Oncology will post -0.54 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/10/ziopharm-oncology-inc-ziop-rating-increased-to-buy-at-zacks-investment-research.html.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper acquired 6,440 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average price of $4.68 per share, for a total transaction of $30,139.20. Following the acquisition, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in ZIOP. Amalgamated Bank raised its position in ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,924 shares during the last quarter. BB&T Securities LLC acquired a new stake in ZIOPHARM Oncology in the 2nd quarter valued at approximately $112,000. Oppenheimer & Co. Inc. raised its position in ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 6,000 shares during the last quarter. Adell Harriman & Carpenter Inc. acquired a new stake in ZIOPHARM Oncology in the 3rd quarter valued at approximately $141,000. Finally, Principal Financial Group Inc. raised its position in ZIOPHARM Oncology by 7.5% in the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 1,673 shares during the last quarter. 41.86% of the stock is currently owned by institutional investors and hedge funds.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.